Navigation Links
Most neuropsychological tests don't tell Alzheimer's disease from vascular dementia
Date:7/8/2009

WASHINGTON Most of the cognitive tests that have been used to decide whether someone has Alzheimer's disease or vascular dementia have not been very helpful when used alone. A new report published by the American Psychological Association concluded that when older people are confused and forgetful, doctors should base their diagnoses on many different types of information, including medical history and brain imaging.

Both Alzheimer's disease and vascular dementia affect learning and memory, behavior and day-to-day function. Even so, they're caused by different problems in the brain and require different medical approaches. It's important to tell them apart accurately, stresses the study in July's Neuropsychology. Valid diagnoses can help doctors treat patients more effectively, and help patients and families better understand their situations.

Jane Mathias, PhD, and Jennifer Burke, M.Psych.(Clinical), both from the University of Adelaide, analyzed 81 previously published studies that compared the cognitive testing of people diagnosed with dementia of the Alzheimer's (4,867) and vascular type (2,263). The average age across participants was 75.

Of the 118 different tests that were used in more than one study, Mathias and Burke found that only two were able to adequately differentiate between Alzheimer's and vascular dementia.

The Emotional Recognition Task (the ability to identify facial expressions in photographs and match emotional expressions to situations, at which people with Alzheimer's were better) and Delayed Story Recall (at which people with vascular dementia were better), were the only tests that appeared to reliably tell the two groups apart.

Even so, whether due to individual variability (people start at different baselines) or possible undiagnosed mixtures of Alzheimer's and vascular disease, there was enough overlap between the two groups to signal the need for more information. Because of these muddied waters, "The combined picture is what's important, so we need to look at how we can improve diagnosis by combining different measures," said Mathias.

Of note, many commonly used tests -- such as Digit Span (repeating a set of numbers forward, backward), verbal fluency (generating words by first letter or category, such as animals), drawing tasks and more were unable to distinguish between dementia types. "While these tests may assist in diagnosing dementia, they do not adequately discriminate between Alzheimer's disease and vascular dementia," wrote the authors. Teasing apart different types of dementia is often harder than deciding whether someone is showing cognitive decline in the first place, Mathias explained.

Although the two tests that worked best would most reliably contribute to a clinical diagnosis, "All cognitive tests should be used cautiously and only in conjunction with other information (imaging, medical history) when diagnosing patients," the authors said.


'/>"/>

Contact: Public Affairs Office
public.affairs@apa.org
202-336-5700
American Psychological Association
Source:Eurekalert

Related medicine news :

1. Selflessness, core of all major world religions, has neuropsychological connection
2. Electric shocks can cause neurologic and neuropsychological symptoms
3. Buyer Beware! Know What Youre Getting When You Buy Online Genetic Tests
4. Larger hospital units have lower miscarriage rates after invasive pregnancy tests
5. Despite More Tests, Some Arent Getting Results
6. Rare sheep could be key to better diagnostic tests in developing world, says Stanford study
7. Newer Blood Tests May Not Improve Heart Risk Assessment
8. Artificial liver for drug tests
9. Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market
10. AMP urges inclusion of molecular diagnostic tests in comparative effectiveness research
11. Legislation Will Expand Access to Life-Saving Laboratory Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... ... 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program of ... team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting ... decide to donate. , “Women’s Hospital at Renaissance has been a collection partner ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a novel low ... Horizon at PEGS 2017 in Boston ... visible particulate matter in biopharmaceutical samples to enable for ... candidate selection and pre-formulation. Halo Labs is ... Elion Labs for system validation. "We are very ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
Breaking Medicine Technology: